Five Melanoma Research Highlights to Look Forward to in 2021
At MRA, every day we are focused on how melanoma research can be reimagined to accelerate progress similar to what has been accomplished in record time with COVID-19 research, and look forward to a future not only void of COVID-19; but where suffering and death due to melanoma are no more.
Fueling a Revolution: Driving Research Forward
MRA is powering a revolution in melanoma research. A revolution that is not only benefiting patients with melanoma but also impacting the field of oncology at large.
Maintaining Momentum in Melanoma Research
The last decade has been one of substantial progress and hope for many melanoma patients, researchers, and clinicians. With 12 new therapeutic approaches now approved to treat melanoma, many advanced-stage patients are seeing their tumors shrink or disappear, and are experiencing renewed hope for a brighter future.
Lighting up Melanoma (One Cell at a Time)
Meet Aditi Sahu, a post-doctoral fellow at Memorial Sloan Kettering Cancer Center, and MRA Dermatology Research Fellow. Learn about her work and MRA's Dermatology Fellowship Award Program.
Melanoma Research Advances – 2019 in Review
During 2019, melanoma research continued its rapid pace of advancement, with FDA approval of a new adjuvant therapy treatment option, several first-in-human clinical trials, and significant progress towards earlier intervention.
2020 Melanoma Mortality Rates Decreasing Despite Ongoing Increase in Incidence
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for...
Brown Skin Too: If You Have Skin, You Can Get Skin Cancer
While pervasive, the myth that people of color don’t need to worry about skin cancer, is entirely untrue. And while the rates of skin cancer among people of color are lower than rates for people with lighter skin, low risk doesn’t mean no risk.
Highlights from the 2019 Scientific Retreat
Over the course of three days, MRA convened over 300 people from across the melanoma research community: patients, doctors, researchers, industry, and government. Participants discussed everything from new treatment approaches such as RNA-based vaccines, strategies to fight back against treatment resistance, and hurdles to testing neo-adjuvant therapies in melanoma.
Police Lieutenant Tackles Melanoma in Phoenix
After being diagnosed with Stage 3 melanoma, Chris Eyrich is committed to raising awareness about melanoma. He works to raise awareness of the unique occupational hazards faced by people who work primarily outdoors, such as police officers and other public servants.